Author
John F. Gerecitano
Also Known As
J Gerecitano, J. F. Gerecitano, J. Gerecitano, J.F. Gerecitano, JOHN GERECITANO, John F Gerecitano, John F. Gerecitano, John Gerecitano
204
Publications
10.5K
Citations
38
H-Index
66
Concepts
All Affiliations
| # | Concept | H-Index | Publications | Citations |
|---|---|---|---|---|
1 | Medicine | 21 | 32 | 4.2K |
2 | Health Sciences | 11 | 11 | 1.3K |
3 | Engineering | 1 | 1 | 23 |
4 | Natural Sciences | 1 | 1 | 293 |
5 | Biomedical Engineering | 1 | 1 | 12 |
John F. Gerecitano
×
77
Publications
10K
Citations
37
H-Index
| Year | Citations | |
|---|---|---|
2015 | 1.8K | |
2015 | 1.1K | |
1994 | 843 | |
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman, Hematological MalignancyMedicineMalignant Blood DisorderImmunologyPharmacology | 2010 | 840 |
2017 | 737 | |
2016 | 315 | |
2009 | 298 | |
2016 | 293 | |
2011 | 280 | |
2015 | 263 |
Page 1
Page 1